Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

Fudan University

Status: Not yet enrolling

Conditions: Sensitivity

Treatments: Other: Neoadjuvant pemetrexed and cisplatin chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT05185544

B2021-Zhan

Details and patient eligibility

About

Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Aged between 18 and 75 years;
• 2. Lung adenocarcinoma;
• 3. The patient is able to receive neoadjuvant pemetrexed and cisplatin chemotherapy
• 4 .The patient is able to understand and comply with the study and has provided written informed consent.

Exclusion criteria

• 1. Patients with a history of lung surgery;
• 2. Postoperative pathology showed non-primary lung cancer;
• 3. Patients with a history of other tumors;
• 4. Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis);
• 5. Unable to cooperate with the researchers because of dementia or cognitive decline
• 6. Other situations that are not in conformity with the standards and requirements of this trial.

Trial design

50 participants in 1 patient group

neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Description:

neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Treatment:

Other: Neoadjuvant pemetrexed and cisplatin chemotherapy